老虎證券
Invest
Pricing
Rewards
Support
About
Quotes
TigerAI
登入
立即註冊
Toggle
港股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
生物醫藥B類股
482.357
-14.363
-2.89%
手動刷新
漲家數:
12
跌家數:
18
平家數:
3
市盈率:
- -
高:
497.296
開:
496.590
低:
481.390
收:
496.720
成交量:
7,829.28萬
成交額:
21.60億
市值:
3,067.82億
流通市值:
2,726.46億
資料載入中...
總覽
新聞資訊
港股收評:恒指漲0.45% 科指跌0.06% 創新藥概念股大漲 存儲概念股下挫
新浪港股
·
09/14
大行評級丨傑富瑞:康方生物依沃西單抗H-2研究取得正面結果,維持「買入」評級
格隆汇
·
09/14
ETF風向標|創新藥板塊領升,港股創新藥ETF、恒生醫藥ETF和港股通醫藥ETF漲4%,短融ETF、科創50ETF上周「吸金」居前
格隆汇
·
09/14
小摩:康方生物(09926.HK)HARMONi-2總生存期數據強勁 維持「增持」評級
智通财经
·
09/14
新股前瞻|攻克抗生素耐藥性難題,普萊醫藥闖關港股能否獲市場下注?
智通财经
·
09/14
港股異動 | 沛嘉醫療-B(09996)升逾3% GeminiOne®經導管緣對緣修復系統註冊申請獲國家藥監局批准
智通财经
·
09/14
ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集 機構看好創新藥投資機會
智通财经
·
09/14
《大行》富瑞:康方生物(09926.HK)依沃西單抗單藥總生存期數據良好
阿斯达克财经
·
09/14
樂高科技、艾迪爾等35家藥企涉商業賄賂,登上貴州醫保基金失信企業「黑榜」
蓝鲸财经
·
09/14
創新藥闖關醫保
国际金融报
·
09/14
A股異動 | 華大智造(688114.SH)升逾8% 虛擬細胞走向工程化落地 公司聯手百圖生科綁定AI製藥下一代基礎設施
智通财经
·
09/14
諾誠健華(09969)股價顯著上升14.18%,現價港幣$15.46
阿斯达克财经
·
09/14
港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯
智通财经
·
09/14
大行評級丨高盛:上調中生製藥目標價至9.07港元,維持「買入」評級
格隆汇
·
09/14
大行評級丨花旗:維持康方生物「買入」評級,HARMONi-2總生存期優效強化ivonescimab差異化優勢
格隆汇
·
09/14
《大行》花旗:康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢
阿斯达克财经
·
09/14
康方生物(09926.HK)升近半成 里昂:Harmoni-2總生存期更新正面
阿斯达克财经
·
09/14
港股異動 | 科濟藥業-B(02171)午前漲近3% FNC清淋預處理方案獲中國專利正式授權
智通财经
·
09/14
《大行》野村:中生製藥(01177.HK)向大股東增購正大天晴5%股權 市場認可交易戰略價值惟對估值存疑
阿斯达克财经
·
09/14
「超30家藥企長期行賄」,涉案醫院回應
澎湃新闻
·
09/14
更多
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BK1574/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":482.35672,"timestamp":1789546124622,"preClose":496.71994,"halted":0,"volume":78292841,"delay":0,"changeRate":-0.028916,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":-14.36322,"latestTime":"09-16 16:00:00","open":496.59045,"high":497.2955,"low":481.3899,"amount":2159910416.1,"amplitude":0.032021,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789522200000,1789531200000],[1789534800000,1789545600000]],"pbRate":3.69899,"peRate":164.598608,"turnoverRate":0.002939,"increases":11,"decrements":18,"flats":3,"marketCap":306781682880,"floatMarketCap":272645614616},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":497.2955,"amplitude":0.032021,"preClose":496.71994,"low":481.3899,"pbRate":"3.69899","latestPrice":482.35672,"volume":78292841,"delay":0,"open":496.59045,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":512.388,"twentyDayClose":492.831,"sixtyDayClose":437.952,"secType":"PLATE","market":"HK","turnoverRate":0.002939,"peRate":164.598608,"marketCap":306781682880,"floatMarketCap":272645614616,"timestamp":1789546124622,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":12,"down":18,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667593836","title":"港股收評:恒指漲0.45% 科指跌0.06% 創新藥概念股大漲 存儲概念股下挫","url":"https://stock-news.laohu8.com/highlight/detail?id=2667593836","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667593836?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 16:08","pubTimestamp":1789373280,"startTime":"0","endTime":"0","summary":"截至收盘,恒生指数涨0.45%,报24917.60,恒生科技指数跌0.06%,国企指数涨0.46%。盘面上,科网股涨跌不一,快手跌超2%,阿里跌超1%,小米涨超3%,联想涨超2%;创新药概念股大涨,诺诚健华涨超14%;汽车股活跃,北京汽车涨超17%;存储概念股跌幅居前,江波龙跌超9%。创新药概念股大涨,诺诚健华涨超14%。广汽集团A股因“重要事项未公告”于9月14日全天紧急停牌。存储概念股跌幅居前,江波龙跌超9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-09-14/doc-inirutny4042987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4505","BK4533","03037","01958","LU0918141887.USD","BK1119","LU0039217434.USD","BK4588","LU1688375341.USD","07200","BK1575","LU1366334578.USD","LU0072462343.USD","07226","LU1235295612.USD","BK1583","82800","LU0048580855.USD","01951","LU0106959298.USD","513600","LU1366334651.USD","LU1880383440.USD","LU2778985437.USD","LU1303224171.USD","LU2294711473.HKD","BABU","LU0791591158.USD","ONLN","LU0823426308.USD","LU1008478684.HKD","BK1539","LU0605514214.HKD","BK4503","LU0791590937.USD","LU0540923850.HKD","LU0588546209.SGD","LU1769817179.HKD","LU1813983027.USD","BBYY","LU1823568750.SGD","BK1161","LU1868838027.USD","02837","IE00BF5LJ272.USD","LU0254981946.USD","LU0348766576.USD","LU0821914370.USD","BK4579","09969","LU1719994722.HKD","81810","BK1193","03033","BK4554","LU0047713382.USD","LU1152091168.USD","LU0545039389.USD","LU0143863198.USD","BK4527","LU0264606111.USD","LU2257852520.SGD","BK1610","LU2097828631.EUR","LU0049112450.USD","03067","LU0084288322.USD","BK1219","LU0345775950.USD","LU2039709279.SGD","BK4581","LU0463099449.HKD","LU0326950275.SGD","LU0449515922.USD","BK1502","LU0531971595.HKD","LU0128522157.USD","LU1769817096.USD","BK4585","LU0417516738.SGD","LU0972618739.USD","LU1046422090.SGD","LU0456846285.SGD","LU0651946864.USD","LU0235996351.USD","LU0572944931.SGD","07552","LU0359201612.USD","LU0348816934.USD","LU1770036033.HKD","LU1051769294.HKD","BK1591","LU0348735423.USD","LU0499858438.USD","02238","LU0543330483.HKD","LU0672654166.SGD","BK4531","LU0251143458.SGD","LU0823413587.USD","LU1808992512.USD","LU0823038988.USD","HK0000306701.USD","LU1023057109.AUD","KSTmain","LU0634319403.HKD","09088","03423","SOCL","LU2148611432.USD","LU1720050803.USD","LU0572940350.SGD","SG9999003461.SGD","BK4526","LU0949170772.SGD","LU0651947912.USD","LU2097828805.USD","LU0128525689.USD","LU0370786039.SGD","LU0149721374.USD","BK1608","LU0553294199.USD","LU1481107354.HKD","LU0348825331.USD","LU1961090484.USD","LU0169518387.USD","LU2087589342.USD","DRAG","03419","LNVGY","LU0449509016.USD","HK0000165453.HKD","LU0320764755.SGD","LU1956131251.USD","BK4535","01024","LU0307460666.USD","HK0000320223.HKD","LU0210526637.USD","LU0067412154.USD","LU0417516902.SGD","LU0531970944.HKD","LU1152091754.HKD","LU0327786744.USD","IE00B0JY6N72.USD","BK4614","LU1242518931.SGD","LU1328277881.USD","LU1242518857.USD","LU0348814723.USD","LU0164872284.USD","LU1282648689.USD","LU0348767384.USD","LU0650527681.SGD","BK4543","XIACY","02833","03417","LU0661504455.SGD","LU0862451753.SGD","LU0029875118.USD","BK4565","LU0051755006.USD","HHImain","LU0054450605.USD","LU0320764599.SGD","LU1770034418.SGD","DRGN","TCHI","LU0456842615.SGD","LU0328353924.USD","BK1095","BK4502","LU0072913022.USD","LU0164865239.USD","LU0499858602.USD","BK1523","HK0000320264.USD","LU2097828557.USD","BABX","09067","LU0594300419.USD","MCHmain","LU0572939691.SGD","LU0880133367.SGD","LU2226246903.HKD","07300","BK4122","BK4220","80992","LU0593848301.USD","LU0675040207.SGD","SG9999001093.SGD","81024","LU1981816686.USD","LU0140636845.USD","83115","LU1048596156.SGD","IE00B3M56506.USD","LU0052750758.USD","HSI","ALBmain","LU0823039010.USD","LU1868837565.USD","LU0890818403.SGD","LU1048588211.SGD","IE0003895053.USD","09988","IE00BFMHRM44.USD","LU0214875030.USD","02800","LU1105468828.SGD","00992","LU1794554557.SGD","LU0310800965.SGD","LU0823413660.USD","LU0823041008.USD","CLIX","BABW","01810","601238","LU0708995583.HKD","HXXD.SI","03032","LU0211977185.USD","KBAB","LU2476274720.SGD","03088","09115","MIUmain","IE0034224299.USD","LU2097828714.EUR","BK1589","BK1597","LU1267930227.SGD","BK4587","LU1003077747.HKD","LU0143863784.USD","BABO","LU0345776255.USD","LU2097828474.EUR","LU0823426480.USD","LU1235294995.USD","LU0052756011.USD","HSTECH","07500","LU0738911758.USD","LU0918141705.HKD","LU0164880469.USD","LU2152927971.USD","LU1880383366.USD","LU0862451837.USD","LU0823397285.USD","LU0979878070.USD","BK4607","LU0244354667.USD","BK1590","LU0700851271.USD","LU0594300179.USD","LU0359202008.SGD","BK4534","LU0871576103.HKD","BK4524","BK1607","BK1506","BK4558","LU2242644610.SGD","LU2476274308.USD","BK1521","BK4575","LU0611395673.USD","LU1046421795.USD","SG9999002463.SGD","LU0359201885.HKD","BK1574","IE0032431581.USD","LU0823040885.USD","LU1323998911.USD","LU1251922891.USD","BK1526","LU0348827113.USD","HK0000306685.HKD","BK1618","LU0823397103.USD","BK1615","BABC","LU0441854154.USD","LU1515016050.SGD","LU0231483743.USD","LU0314109678.HKD","LU0797268264.HKD","LU1051768304.USD","LU1188198961.HKD","BABA","BK4504","LU0117841782.USD","688428","BK4548","LU0501845795.SGD","LU2399975544.HKD","HK0000286598.CNH","LU0561508036.HKD","BK4538","LU1785774172.SGD","LU0456827905.SGD","03115"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656624","title":"大行評級丨傑富瑞:康方生物依沃西單抗H-2研究取得正面結果,維持「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656624","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656624?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:59","pubTimestamp":1789372758,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1720050803.USD","IE00B5MMRT66.SGD","LU1961090484.USD","LU2476274720.SGD","LU1794554557.SGD","IE00B543WZ88.USD","LU0348766576.USD","LU0348783233.USD","LU2476274308.USD","LU0561508036.HKD","LU0348735423.USD","LU0348784397.USD","LU0634319403.HKD","LU0348827113.USD","KURE","LU2399975544.HKD","09926","BK1161","LU0417516571.SGD","BK1574","LU0348767384.USD","LU2488822045.USD","LU0540923850.HKD","LU2778985437.USD","IE00BPRC5H50.USD","LU0417516902.SGD","LU0417516738.SGD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656312","title":"ETF風向標|創新藥板塊領升,港股創新藥ETF、恒生醫藥ETF和港股通醫藥ETF漲4%,短融ETF、科創50ETF上周「吸金」居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656312","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656312?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:48","pubTimestamp":1789372094,"startTime":"0","endTime":"0","summary":"8张图速览","market":"sh","thumbnail":"https://img3.gelonghui.com/c22ef-7f006f6d-0c57-40d1-bf4f-5bf2a2ea4eca.jpg?guru_height=2160&guru_width=4096&guru_size=709194","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/c22ef-7f006f6d-0c57-40d1-bf4f-5bf2a2ea4eca.jpg?guru_height=2160&guru_width=4096&guru_size=709194"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/6641832","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_fund_highlight","symbols":["159992","159929","159316","06978","BK1574","BK1161","159681"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667656089","title":"小摩:康方生物(09926.HK)HARMONi-2總生存期數據強勁 維持「增持」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2667656089","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667656089?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:38","pubTimestamp":1789371481,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0348827113.USD","IE00B5MMRT66.SGD","LU2488822045.USD","09926","LU1794554557.SGD","LU0348783233.USD","LU2778985437.USD","IE00B543WZ88.USD","KURE","LU2399975544.HKD","LU0634319403.HKD","LU0417516902.SGD","LU0561508036.HKD","LU0348735423.USD","LU0348784397.USD","LU0348825331.USD","LU1720050803.USD","BK1574","BK1161","LU0417516738.SGD","LU0540923850.HKD","LU2476274720.SGD","LU0348767384.USD","LU0348766576.USD","IE00BPRC5H50.USD","LU2476274308.USD","LU0417516571.SGD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667765505","title":"新股前瞻|攻克抗生素耐藥性難題,普萊醫藥闖關港股能否獲市場下注?","url":"https://stock-news.laohu8.com/highlight/detail?id=2667765505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667765505?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:36","pubTimestamp":1789371362,"startTime":"0","endTime":"0","summary":"近日,普莱医药向港交所主板递交上市申请,中信证券担任独家保荐人,这是公司继2月13日首次提交上市申请后的第二次递表。目前的治疗药物以唑类抗真菌药为主,但耐药性问题同样存在。目前该产品正在中国进行一项II期临床试验,且已获FDA批准在美国进行一项II期临床试验。整体来看,在全球抗生素耐药性问题日益严峻的背景下,抗菌肽作为新型抗感染药物具备广阔的市场前景。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1515","KCAI","BK1161","BK1574","BK4588","159938","BK4585","09939"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2667563655","title":"港股異動 | 沛嘉醫療-B(09996)升逾3% GeminiOne®經導管緣對緣修復系統註冊申請獲國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2667563655","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667563655?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:18","pubTimestamp":1789370281,"startTime":"0","endTime":"0","summary":"消息面上,9月11日,沛嘉医疗-B发布公告,公司自主研发的GeminiOne经导管缘对缘修复系统近期已获中华人民共和国国家药品监督管理局批准其注册申请。GeminiOne获批标志着集团正式进入二尖瓣反流的商业化治疗领域,并代表集团在主动脉瓣狭窄及主动脉瓣反流治疗既有布局的基础上,进一步显著扩充其经导管瓣膜治疗产品组合。GeminiOne之EU MDR CE标志注册申请已提交,而美国早期可行性研究现正进行中。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09996","BK4588","KCAI","BK1583","BK4585","BK1100","VXUS","BK1574","159891"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667554366","title":"ETF異動 | 華夏恒生生科(03069)升逾4% WCLC臨床數據催化密集 機構看好創新藥投資機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2667554366","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667554366?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:17","pubTimestamp":1789370250,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,华夏恒生生科涨超4%。截至发稿,涨4.01%,报15.58港元,成交额6924.78万港元。本次WCLC会议上,中国新药表现亮眼,入选口头报告研究19项,小型口头报告研究45项,刷新记录。国金证券称,创新药企业扭亏节点到来,全年临床数据催化密集,叠加已BD出海管线海外临床进展顺利,看好创新药板块投资机会。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03069","LNGR","IBBQ","BK4588","FDN","06978","BK1574","BK4550","159992","BK1161","MEDX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667655595","title":"《大行》富瑞:康方生物(09926.HK)依沃西單抗單藥總生存期數據良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2667655595","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667655595?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 15:06","pubTimestamp":1789369560,"startTime":"0","endTime":"0","summary":"富瑞发表研究报告指,康方生物(09926.HK) 依沃西单抗(Ivonescimab)H-2研究取得正面结果,数据显示,其中期总生存期(OS)具统计学显著性,单药一线治疗PD-L1阳性非小细胞肺癌较帕博利珠单抗(Pembrolizumab)OS显著延长,OS中位数为30.8个月,风险比为0.73,中位随访36个月,对比帕博利珠单抗OS中位数为22.6个月。富瑞指出,康方生物依沃西单抗拥有总生存期优势,数据令人鼓舞,维持“买入”评级及目标价226元。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2026-09-14 12:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200424093930528_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200424093930528_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544311/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544311/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU2488822045.USD","09926","LU0348827113.USD","LU0417516571.SGD","LU0561508036.HKD","BK1161","LU0348783233.USD","BK1574","LU2399975544.HKD","KURE","LU1720050803.USD","LU2476274720.SGD","LU0348825331.USD","LU0634319403.HKD","LU1961090484.USD","LU0348766576.USD","LU0348735423.USD","LU1794554557.SGD","LU2476274308.USD","LU0348784397.USD","LU2778985437.USD","LU0540923850.HKD","IE00B5MMRT66.SGD","LU0348767384.USD","IE00BPRC5H50.USD","LU0417516738.SGD","IE00B543WZ88.USD","LU0417516902.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667536746","title":"樂高科技、艾迪爾等35家藥企涉商業賄賂,登上貴州醫保基金失信企業「黑榜」","url":"https://stock-news.laohu8.com/highlight/detail?id=2667536746","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667536746?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:51","pubTimestamp":1789368717,"startTime":"0","endTime":"0","summary":"根据公告,对于配送企业,根据信用评价结果限制或中止配送企业在贵州省的配送资格1-5年;对于生产企业,除提醒告诫、提示风险外,限制或中止相关涉案产品或全部产品挂网、投标资格。据悉,贵州省医保基金运行服务中心给出了修复信用评级的方法。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789368658648386760","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["AGNG","BK1583","GDOC","BK1574","LNGR","MEDX","09996","IEIH","PTH","HART","MDEV","LGHT","BK1100","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667653941","title":"創新藥闖關醫保","url":"https://stock-news.laohu8.com/highlight/detail?id=2667653941","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667653941?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:46","pubTimestamp":1789368365,"startTime":"0","endTime":"0","summary":"张力制图9月5日至8日,2026年国家基本医保药品目录现场谈判(下称“国谈”)竞价工作在北京开展,上百家国内外药企代表到场参与。本次共有124个目录外药品入围谈判竞价环节,肿瘤、罕见病、慢性病、儿童用药等社会关注度较高的创新药均在列,有望通过谈判纳入新版国家医保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873368645.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873368645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","MEDX","LNGR","159992","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667588066","title":"A股異動 | 華大智造(688114.SH)升逾8% 虛擬細胞走向工程化落地 公司聯手百圖生科綁定AI製藥下一代基礎設施","url":"https://stock-news.laohu8.com/highlight/detail?id=2667588066","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667588066?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 14:02","pubTimestamp":1789365758,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,华大智造午后涨超8%,截至发稿,涨7.36%,报58.37元,成交额3.81亿元。消息面上,9月11日,全栈生命科学工具全球提供商华大智造与生命科学基础大模型全球领跑者百图生科达成战略合作:双方将面向具体客户和研发场景,共建专属细胞大模型,并以此为底座,开发面向虚拟细胞、虚拟扰动的专属高质量数据产出基础设施。AI4S基座龙头与AI4S头部大模型的联手,落点是行业最稀缺的高质量数据产能。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02827","BK0251","BK1191","03130","BK1574","CHAT","ARTY","83130","02846","QTOC","159982","AIPO","01477","07233","399300","AGIX","688114","VTHR","BK1147","03188","83188","82846"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667302276","title":"諾誠健華(09969)股價顯著上升14.18%,現價港幣$15.46","url":"https://stock-news.laohu8.com/highlight/detail?id=2667302276","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667302276?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:45","pubTimestamp":1789364700,"startTime":"0","endTime":"0","summary":"[上升股]诺诚健华(09969) 股价在下午01:44比前收市价显著上升14.18%,现股价为港币$15.46。至目前为止,今日最高价为$15.46,而最低价为$13.38。总成交量为1.261千万股,总成交金额为港币$1.864亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141428/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2609141428/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["688428","BK1574","BK0239","BK1161","09969"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608630","title":"港股異動 | 創新藥概念股全線走高 WCLC臨床數據重磅催化 機構指回調後配置價值凸顯","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608630","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667608630?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:39","pubTimestamp":1789364389,"startTime":"0","endTime":"0","summary":"消息面上,9月12-15日,2026年世界肺癌大会召开,多项中国创新药临床数据集中亮相,康方生物依沃西单药OS数据、B7H3ADC等成为焦点。中泰证券指出,WCLC集中披露的多项肺癌领域临床进展,进一步验证了中国创新药的临床价值和全球竞争力,或可积极把握创新药回调后的配置机会。机构普遍认为,三季度部分企业新增订单进入收入确认期,基本面有望持续改善。当前医药板块估值27倍PE,低于历史均值,回调后配置价值凸显。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0561508036.HKD","KCAI","LU0634319403.HKD","06978","LU1961090484.USD","IBBQ","KURE","159992","BK4588","LU0348767384.USD","01177","LU0348735423.USD","LU0455707207.USD","LU2476274308.USD","LU0607220059.USD","BK1593","LU0348784397.USD","LU2488822045.USD","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU0417516571.SGD","LU0417516738.SGD","01801","LU2097828805.USD","LU2097828714.EUR","HK0000165453.HKD","LU0348827113.USD","MEDX","LU2476274720.SGD","09969","LNGR","LU1831875114.USD","09926","LU0244354667.USD","LU1188198961.HKD","LU0348825331.USD","LU2097828557.USD","BK1574","LU0326950275.SGD","LU1969619763.USD","BK1191","LU0348766576.USD","01530","BK1161","IE00BZ08YR35.GBP","BK1521","LU2242644610.SGD","LU2778985437.USD","BK1589","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637715","title":"大行評級丨高盛:上調中生製藥目標價至9.07港元,維持「買入」評級","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637715","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637715?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:27","pubTimestamp":1789363638,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1191","BK1574","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637732","title":"大行評級丨花旗:維持康方生物「買入」評級,HARMONi-2總生存期優效強化ivonescimab差異化優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637732","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667637732?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 13:24","pubTimestamp":1789363448,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["09926","IE00B5MMRT66.SGD","LU0634319403.HKD","KURE","LU0561508036.HKD","LU0348735423.USD","LU0540923850.HKD","LU2488822045.USD","IE00B543WZ88.USD","LU0348784397.USD","LU0348827113.USD","LU2476274720.SGD","LU1794554557.SGD","IE00BPRC5H50.USD","BK1574","LU2476274308.USD","LU0417516902.SGD","LU0348767384.USD","LU0348825331.USD","LU0417516571.SGD","LU0417516738.SGD","BK1161","LU2778985437.USD","LU0348766576.USD","LU1720050803.USD","LU0348783233.USD","LU2399975544.HKD","LU1961090484.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632069","title":"《大行》花旗:康方生物(09926.HK)HARMONi-2總生存期優效強化ivonescimab差異化優勢","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632069","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632069?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 12:14","pubTimestamp":1789359240,"startTime":"0","endTime":"0","summary":"花旗发表研究报告指,康方生物的HARMONi-2中期读数显示,ivonescimab作为PD-L1阳性非小细胞肺癌一线单药治疗,对比pembrolizumab展现有意义的总生存期优效,强化其差异化定位,全球读数仍是关键。该行指出,HARMONi-2在234宗总生存期事件下,ivonescimab的中位总生存期为30.75个月;总生存期获益在PD-L1 TPS > 50%及鳞状非小细胞肺癌,整体存活期获益最为明显,安全性大致相若。该行维持康方生物“买入”评级,目标价171港元不变。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20200914151046636_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20200914151046636_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544280/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09926","LU1720050803.USD","LU2399975544.HKD","LU0348827113.USD","LU2476274308.USD","LU0348766576.USD","LU0417516738.SGD","LU1961090484.USD","LU0540923850.HKD","BK1574","LU0561508036.HKD","LU2778985437.USD","LU0417516902.SGD","LU2488822045.USD","LU0348767384.USD","BK1161","LU2476274720.SGD","LU0348825331.USD","LU0634319403.HKD","LU0348783233.USD","LU0348784397.USD","IE00BPRC5H50.USD","KURE","IE00B5MMRT66.SGD","LU1794554557.SGD","LU0417516571.SGD","IE00B543WZ88.USD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632490","title":"康方生物(09926.HK)升近半成 里昂:Harmoni-2總生存期更新正面","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632490","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632490?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:57","pubTimestamp":1789358220,"startTime":"0","endTime":"0","summary":"康方生物今日高开4.49%,最高见96.55元。里昂发表研究报告指,康方生物公布Harmoni-2正面总生存期更新,ivonescimab录得中位OS 30.75个月,对比pembrolizumab 22.57个月,风险比为0.73,显示具统计学意义及临床意义的生存获益。该行认为,该药OS结果符合投资者预期,并为医生提供更多ivonescimab临床表现优于pembrolizumab的证据,尽管风险比不及Harmoni-6的0.66更新吸引;OS数据亦较2025年4月中国标签更新时风险比0.78有所改善。Harmoni-3无进展生存期读出,以及美国FDA于今年下半年就ivonescimab的决定,为后续关键催化剂。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230531145638513_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544272/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544272/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU1961090484.USD","LU0348827113.USD","09926","LU0348767384.USD","IE00BPRC5H50.USD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0540923850.HKD","LU0634319403.HKD","LU2399975544.HKD","IE00B543WZ88.USD","LU2488822045.USD","LU1720050803.USD","LU0348784397.USD","LU0561508036.HKD","LU0348825331.USD","LU0348735423.USD","LU2778985437.USD","BK1161","LU1794554557.SGD","LU2476274720.SGD","LU0417516738.SGD","LU0417516571.SGD","LU0348783233.USD","LU0348766576.USD","LU2476274308.USD","BK1574","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667321696","title":"港股異動 | 科濟藥業-B(02171)午前漲近3% FNC清淋預處理方案獲中國專利正式授權","url":"https://stock-news.laohu8.com/highlight/detail?id=2667321696","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667321696?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:54","pubTimestamp":1789358057,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,科济药业-B午前涨近3%,截至发稿,涨2.47%,报12.86港元,成交额1644.03万港元。消息面上,9月14日,据科济药业官微消息,公司自主研发的FNC清淋预处理方案正式获得中国国家知识产权局专利授权。此次FNC清淋预处理方案在中国获得专利授权,意味着公司对恺力美的保护已从单一产品层面,延伸至涵盖清淋预处理在内的整体治疗方案层面,提升了同类竞品的研发与商业化门槛,进一步巩固了公司在实体瘤CAR-T领域的领先地位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","VXUS","02171","BK1587","BK1161","KCAI","BK4585","BK1585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667632971","title":"《大行》野村:中生製藥(01177.HK)向大股東增購正大天晴5%股權 市場認可交易戰略價值惟對估值存疑","url":"https://stock-news.laohu8.com/highlight/detail?id=2667632971","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667632971?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:51","pubTimestamp":1789357860,"startTime":"0","endTime":"0","summary":"野村发表报告指,中生制药将以现金约44.8亿元人民币,向执行董事兼主要股东谢承润增购非上市附属公司正大天晴额外5%股权,交易按正大天晴股权估值896亿元人民币计算,完成后,中生制药持股将由60%升至65%。野村维持对中生制药“买入”评级,目标价8.67元。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190604131528273_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544269/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1544269/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1521","01177","BK1589","IE00BZ08YT58.USD","BK1574","01477","BK1515","HK0000165453.HKD","BK1191","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667863208","title":"「超30家藥企長期行賄」,涉案醫院回應","url":"https://stock-news.laohu8.com/highlight/detail?id=2667863208","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667863208?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 11:36","pubTimestamp":1789356960,"startTime":"0","endTime":"0","summary":"澎湃新闻首席记者 李潇潇9月13日,国家医保局发布《医疗机构涉医药购销商业贿赂案》一文提到,仅2025年下半年,河北医科大学第二医院就涉及9件司法刑事判决。在国家医保局9月13日最新披露的信息中,有超过30家医药企业长期对河北医科大学第二医院工作人员行贿。具体到河北祥恩医疗器械贸易有限公司一家,该公司为向河北医科大学第二医院销售价格虚高的医疗耗材,累计向该医院工作人员行贿2064万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-14/doc-iniruhxa7301443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["MEDX","MDEV","AGNG","IEIH","PTH","RSPH","09996","BK1100","GDOC","HART","LNGR","BK1583","BK1574","LGHT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":17,"pageCount":4,"totalSize":335,"code":"91000000","status":"200"}]}}